Since the original publications describing the approach 14,15, the original library of 180 GST-kinases has been expanded to 420 members, or ~80% of the human protein kinome. With the expanded library, the protocol as described takes 4-5 days and then 1-4 days to develop films (as deemed necessary), which could be shortened by use of phosphorimaging and digital signal enhancement. There are several key steps where care must be taken (See Figure 1 for overview of protocol). First, is the health of the stock of cells (mycoplasma free, never allowed to reach confluence during expansion, and treated with trypsin at each passage) during the batch expansion stage and in the 96 well plates at the time of transfection. Cells should be uniformly seeded, and 80% confluent when transfection takes place (Step 1.5).
Second, it is ideal during the transfection to use an automated liquid dispenser to minimize volume transfer errors, thus limiting coefficient of variations (“cvs”) between wells. For small volumes, fitting the dispenser with a smaller volume cassette limits reagent loss due to reduced dead volumes and increases dispensing accuracy. The treatment step with sodium pervanadate, a pan tyrosine phosphatase inhibitor, is used as a general stimulus to increase phosphorylation status of target kinases. Inclusion of calcium at this step increases cell-matrix adhesion, preventing cell loss due to rounding elicited by prolonged pervanadate treatment. This step should be done with strict adherence to the 10 minute incubation time.
Third, for the kinase assay itself, there are several considerations when selecting the recombinant substrate: peptides, protein domains, or intact proteins as large as 120 kDa can all be used. If a specific phosphorylation site is known, a peptide substrate is the most straight-forward approach, but needs to be large enough to detect on a SDS-PAGE gel. Thus, peptide substrates can be fused to GST and purified from bacteria to give a MW of >25. Larger proteins have the advantage that they are likely folded and their phosphorylatable residues exposed as they would be in the cell, yet come with the drawback that they will include additional residues that could be phosphorylated and give signal in the assay. Our preference is to run a screen using a peptide substrate composed of 15-20 amino acids surrounding a residue that is known to be phosphorylated in vivo and is known to regulate a biological event, as this renders validation of the candidate kinases from the screen both in vitro and in vivo much faster.
Last, ideally the amount of protein approaches or exceeds 1 µg per well; this of course varies with the MW of the substrate. Less protein per well can yield meaningful hits, but the ‘more is better’ rule applies as it increases signal:noise. Standard, non-gradient gels are recommended as gradient gels crack too often during drying. After drying the gels, detection of a radioactive signal over background with a Geiger counter gives an excellent indication of success of the assay.
As the screen is in vitro and additional levels of complexity exist in vivo, a candidate kinase(s) for a given substrate must be validated in cells. Specifically, the screen may identify a family member that has the biochemical capacity to phosphorylate the substrate in vitro, yet is not expressed in the same cell type or in the same subcellular compartment as the substrate. For example, while MARK2 and MARK3 were both hits in a screen for kinase that could phosphorylate CRTC2 on Ser275, only MARK2 formed a complex with the substrate in cells 14. The following are a series of additional experiments that can be used to confirm the physiological relevance of a candidate kinase. First, mobility shifts of the substrate on SDS-PAGE following coexpression of the candidate kinase can be used as a confirmation control. Appropriate controls such cotransfection of a catalytically inactive kinase can confirm specificity. Second, the substrate can be immunoprecipitated from cell extracts that have been incubated with 32P-orthophosphate to confirm incorporation of phosphate into the substrate in the presence of the wildtype and not a catalytically inactive kinase. Third, a phosphospecific antibody can be generated against the phosphoacceptor sequence (if known) and used to confirm an increase in substrate phosphorylation when the kinase is overexpressed. A secondary screen using a mutant substrate carrying a non-phosphorylatable residue at the target site can confirm specificity prior to generation of a phosphoantibody, a particularly important control with larger domain and full-length protein substrates. Pharmacological inhibition approaches to inhibit a candidate kinase can also be used, yet caution must be exercised as inhibition of related kinases is an underappreciated reality. Last, RNAi-mediated silencing of the candidate kinase(s) in cells followed and western blotting to monitor loss of target site phosphorylation with a phosphospecific antibody can be performed.